35264783 31694223 30624988 30525180 30705378 31183617 34547175 34001723 29589184 34327445 31916065 32066287 34714114 29480403 - Search Results

Year	Number of Results
2018	3
2019	5
2020	3
2021	2
2022	2

1

Application of omics in hypertension and resistant hypertension.

Guo J, Guo X, Sun Y, Li Z, Jia P. Guo J, et al. Hypertens Res. 2022 May;45(5):775-788. doi: 10.1038/s41440-022-00885-5. Epub 2022 Mar 9. Hypertens Res. 2022. PMID: 35264783 Review.

2

Resistant/Refractory Hypertension and Sleep Apnoea: Current Knowledge and Future Challenges.

Oscullo G, Torres G, Campos-Rodriguez F, Posadas T, Reina-González A, Sapiña-Beltrán E, Barbé F, Martinez-Garcia MA. Oscullo G, et al. J Clin Med. 2019 Nov 5;8(11):1872. doi: 10.3390/jcm8111872. J Clin Med. 2019. PMID: 31694223 Free PMC article. Review.

3

Potential Strategies to Reduce Blood Pressure in Treatment-Resistant Hypertension Using Food and Drug Administration-Approved Nanodrug Delivery Platforms.

Fancher IS, Rubinstein I, Levitan I. Fancher IS, et al. Hypertension. 2019 Feb;73(2):250-257. doi: 10.1161/HYPERTENSIONAHA.118.12005. Hypertension. 2019. PMID: 30624988 Free PMC article. Review. No abstract available.

4

Resistant and refractory hypertension: two sides of the same disease?

Muxfeldt ES, Chedier B, Rodrigues CIS. Muxfeldt ES, et al. J Bras Nefrol. 2019 Apr-Jun;41(2):266-274. doi: 10.1590/2175-8239-jbn-2018-0108. Epub 2018 Dec 6. J Bras Nefrol. 2019. PMID: 30525180 Free PMC article.

5

Apparent Treatment-Resistant Hypertension and Cardiovascular Risk in Hemodialysis Patients: Ten-Year Outcomes of the Q-Cohort Study.

Tanaka S, Ninomiya T, Hiyamuta H, Taniguchi M, Tokumoto M, Masutani K, Ooboshi H, Nakano T, Tsuruya K, Kitazono T. Tanaka S, et al. Sci Rep. 2019 Jan 31;9(1):1043. doi: 10.1038/s41598-018-37961-1. Sci Rep. 2019. PMID: 30705378 Free PMC article.

6

The Potential Role of Obstructive Sleep Apnoea in Refractory Hypertension.

Oscullo G, Sapiña-Beltrán E, Torres G, Zaldivar E, Barbé F, Martinez-Garcia MA. Oscullo G, et al. Curr Hypertens Rep. 2019 Jun 10;21(8):57. doi: 10.1007/s11906-019-0963-6. Curr Hypertens Rep. 2019. PMID: 31183617 Review.

7

Resistance to antihypertensive treatment and long-term risk: The Atherosclerosis Risk in Communities study.

Wijkman MO, Malachias MVB, Claggett BL, Cheng S, Matsushita K, Shah AM, Jhund PS, Coresh J, Solomon SD, Vardeny O. Wijkman MO, et al. J Clin Hypertens (Greenwich). 2021 Oct;23(10):1887-1896. doi: 10.1111/jch.14269. Epub 2021 Sep 21. J Clin Hypertens (Greenwich). 2021. PMID: 34547175 Free PMC article.

8

Aprocitentan (a Dual Endothelin-Receptor Antagonist) for Treatment-Resistant Hypertension.

McCoy EK, Lisenby KM. McCoy EK, et al. J Cardiovasc Pharmacol. 2021 Jun 1;77(6):699-706. doi: 10.1097/FJC.0000000000001023. J Cardiovasc Pharmacol. 2021. PMID: 34001723 Review.

9

Controlled Versus Uncontrolled Resistant Hypertension: Are They in the Same Bag?

Yugar-Toledo JC, Brunelli V, Vilela-Martin JF, Fattori A, Moreno H. Yugar-Toledo JC, et al. Curr Hypertens Rep. 2018 Mar 27;20(3):26. doi: 10.1007/s11906-018-0825-7. Curr Hypertens Rep. 2018. PMID: 29589184 Review.

10

Managing Hypertension in the elderly: What's new?

Aronow WS. Aronow WS. Am J Prev Cardiol. 2020 May 1;1:100001. doi: 10.1016/j.ajpc.2020.100001. eCollection 2020 Mar. Am J Prev Cardiol. 2020. PMID: 34327445 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results